Companies · Other Health Care

Breakthrough Products, Inc.

DENVER · Other Health Care

Diligence memoA one-page analyst read on Breakthrough Products, Inc. — recommendation, valuation, rhythm, risks.
$38.8M
Total raised · real
8
Rounds
0.6×
Latest step-up
Top 11%
Sector rank · raised
Series B
Latest stage · inferred · Fri Apr 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Breakthrough Products, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.99× the median modeled value of Series B Other Health Care companies in 2013–2015 (85 peers) — value vs value, same stage and era.
  • Within the normal band (99% of peer median) for its niche.
Dormant
  • Last raise 12.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Breakthrough Products, Inc. is one of 5376 Other Health Care companies tracked from DENVER. By capital raised it ranks among the largest (ahead of 90% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2010-03-19 Raised $1.0M (real) Modeled valuation $26M (est)Seed2010Pre-Seed · 2010-03-19 Raised $100K (real) Modeled valuation $3.1M (est)Pre-Seed2010Seed · 2010-03-19 Raised $1.0M (real) Modeled valuation $26M (est)Seed2010Seed · 2010-12-06 Raised $450K (real) Modeled valuation $11M (est)Seed2010Seed · 2012-02-03 Raised $1.1M (real) Modeled valuation $27M (est)Seed2012Seed · 2013-03-22 Raised $2.5M (real) Modeled valuation $62M (est)Seed2013Seed · 2013-10-16 Raised $2.0M (real) Modeled valuation $50M (est)Seed2013Series B · 2014-04-04 Raised $20M (real) Modeled valuation $437M (est)Series B2014Series A · 2014-04-04 Raised $12M (real) Modeled valuation $240M (est)Series A2014+$100K+$1.0M+$450K+$1.1M+$2.5M+$2.0M+$20M+$12MCumulative $40M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.0M · 2010
Bridge · Seed-stage$100K · 2010smaller follow-on
Seed extension$1.0M · 2010
Seed extension$450K · 2010
Seed extension$1.1M · 2012
Seed extension$2.5M · 2013
Seed extension$2.0M · 2013
Series B$19.7M · 2014no Series A on file
Bridge · Series B-stage$11.9M · 2014smaller follow-on

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$437.0M
Base estimate est.
$46.4M
Conservative case
$1.7B
Upside case
$109.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $25.6M · 2010-03-192010Pre-Seed · modeled $3.1M · 2010-03-19Seed · modeled $25.6M · 2010-03-19Seed · modeled $11.2M · 2010-12-06Seed · modeled $27.3M · 2012-02-03Seed · modeled $62.0M · 2013-03-22Seed · modeled $49.6M · 2013-10-16Series B · modeled $437.0M · 2014-04-04Series A · modeled $240.2M · 2014-04-042014
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
6.0 yr
Elapsed time used
12.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$9.6M/yr
Capital velocity
16.3 yr
On record since
2010
First round
9
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 16× above median
This company$38.8M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.7× of median
This company$11.9M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 20× above median
This company$437.0M
Sector median$22.1M

Raised more than 90% of sector peers (real $). Modeled value above 92% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #46 of 85.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Drynachan, Llc · Series B Raised $40.0M · modeled $886.2M (est)Vistria SHC Holdings, LLC · Series B Raised $39.7M · modeled $879.5M (est)Ebh Holding Company, Inc. · Series B Raised $70.9M · modeled $871.1M (est)Orthopediatrics Corp · Series B Raised $57.5M · modeled $864.0M (est)Assurerx Health, Inc · Series B Raised $51.5M · modeled $828.4M (est)IMRIS Inc. · Series B Raised $36.8M · modeled $816.0M (est)Remedy Partners, Inc. · Series B Raised $56.4M · modeled $795.3M (est)Hansen Medical Inc · Series B Raised $126.0M · modeled $775.4M (est)BCOM Investment Partners, LLC · Series B Raised $34.5M · modeled $764.3M (est)Michigan Critical Care Consultants, Inc. · Series B Raised $34.0M · modeled $753.2M (est)HY Holdings, Inc. · Series B Raised $33.0M · modeled $731.1M (est)Medical Solutions L.L.C. · Series B Raised $32.5M · modeled $720.0M (est)Breakthrough Products, Inc. (this company) Raised $38.8M · modeled $437.0M (est)Breakthrough Products, Inc.
CompanyStageRaised · realValue · estvs peer med.
Drynachan, LlcSeries B$40.0M$886.2M2.00×
Vistria SHC Holdings, LLCSeries B$39.7M$879.5M1.99×
Ebh Holding Company, Inc.Series B$70.9M$871.1M1.97×
Orthopediatrics CorpSeries B$57.5M$864.0M1.95×
Assurerx Health, IncSeries B$51.5M$828.4M1.87×
IMRIS Inc.Series B$36.8M$816.0M1.84×
Remedy Partners, Inc.Series B$56.4M$795.3M1.79×
Hansen Medical IncSeries B$126.0M$775.4M1.75×
BCOM Investment Partners, LLCSeries B$34.5M$764.3M1.72×
Michigan Critical Care Consultants, Inc.Series B$34.0M$753.2M1.70×
HY Holdings, Inc.Series B$33.0M$731.1M1.65×
Medical Solutions L.L.C.Series B$32.5M$720.0M1.62×
Breakthrough Products, Inc. this companySeries B$38.8M$437.0M0.99×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.0M2010-03-19$5.2M$25.6M90%
Pre-Seed$100K2010-03-19$556K$3.1M90%
Seed$1.0M2010-03-19$5.2M$25.6M90%
Seed$450K2010-12-06$2.3M$11.2M90%
Seed$1.1M2012-02-03$5.5M$27.3M90%
Seed$2.5M2013-03-22$12.5M$62.0M90%
Seed$2.0M2013-10-16$10.0M$49.6M90%
Series B$19.7M2014-04-04$109.6M$437.0M90%
Series A$11.9M2014-04-04$54.1M$240.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.0M2010-03-19
    • First recorded raise — entered as Seed.
  2. Pre-Seed$100K2010-03-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 10.3× smaller than the prior — bridge or down round.
  3. Seed$1.0M2010-03-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 10.3× larger than the prior — scaling up.
  4. Seed$450K2010-12-06
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
  5. Seed$1.1M2012-02-03
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
  6. Seed$2.5M2013-03-22
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
  7. Seed$2.0M2013-10-16
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  8. Series B$19.7M2014-04-04
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 9.9× larger than the prior — scaling up.
  9. Series A$11.9M2014-04-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
Intelligence
2014 ~Q4
Modeled next raise · ~6mo cadence
$11.9M
Modeled next size est.range $11.9M$19.0M
0.6×
Last step-up
$9.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert King6 other2012-02
Randall Kaplan3 other2012-02
Michael J. Valentino2 other2014-04
Candace J. Crawford2014-04
Dave Leyrer2013-03
David T. Leyrer2014-04
Jordan Eisenberg2010-03
Lynne J. Millheiser2014-04
Mike Valentino2013-10
Philip Levin2010-03
Ronald T. Fugate2014-04
Ron Fugate2014-04
Registry & provenance

Breakthrough Products, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1488401
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Urotronic, Inc.Other Health CareSeries B$38.5M$253.7Msame sector · same stage
TherOx, Inc.Other Health CareSeries B$38.4M$332.3Msame sector · same stage
Theator Inc.Other Health CareSeries B$38.2M$291.7Msame sector · same stage
BrainScope Company, Inc.Other Health CareSeries B$37.8M$363.0Msame sector · same stage
Artis Holdings, LLCOther Health CareSeries B$40.0M$383.2Msame sector · same stage
Imagine Pediatrics Holdings LLCOther Health CareSeries B$37.6M$201.0Msame sector · same stage
Clarient, IncOther Health CareSeries B$40.0M$241.7Msame sector · same stage
Surface Ophthalmics, Inc.Other Health CareSeries B$40.1M$422.1Msame sector · same stage
Frequently asked
How much funding has Breakthrough Products, Inc. raised?
Breakthrough Products, Inc. has raised approximately $38.8M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Breakthrough Products, Inc.'s estimated valuation?
Provath's modeled valuation for Breakthrough Products, Inc. is approximately $437.0M (modeled range $46.4M–$1.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Breakthrough Products, Inc. at?
Breakthrough Products, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Apr 04.
What does Breakthrough Products, Inc. do and where is it based?
Breakthrough Products, Inc. operates in the Other Health Care sector, based in DENVER.
Explore related

See where Breakthrough Products, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Breakthrough Products, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.